Products listed on this website are the main products that Astellas provides globally. These products may not be available in all countries or regions and may be available under different brand names and trademarks, for different indications and patient populations, in different dosages, and in different strengths. These products generally are available only by prescription through local healthcare professionals.
Please visit our local country or region websites for local product information.
XTANDI™ (enzalutamide)
XTANDI is a treatment for prostate cancer.
PADCEV™ (enfortumab vedotin)
PADCEV is a treatment for urothelial cancer.
XOSPATA™ (gilteritinib)
XOSPATA is a treatment for acute myeloid leukemia (AML).
VYLOY™ (zolbetuximab)
VYLOY is a treatment for gastric cancer.
VEOZAH™ (fezolinetant)
VEOZAH is a treatment for moderate to severe vasomotor symptoms due to menopause.
IZERVAY™ (avacincaptad pegol)
IZERVAY is a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
EVRENZO™ (roxadustat)
EVRENZO is a treatment for anemia associated with chronic kidney disease (CKD).
BETANIS™/MYRBETRIQ™/BETMIGA™ (mirabegron)
BETANIS/MYRBETRIQ/BETMIGA is a treatment for overactive bladder (OAB).
PROGRAF™ (tacrolimus)
PROGRAF is an immunosuppressant.
Please refer to the Supplementary Documents (pdf) of the Business Results in regard to the sales of major products in each region, including the products above.